Exchange: OTC Sector: Healthcare Industry: Biotechnology
2.63% $0.195
America/New_York / 14 des 2023 @ 15:44
FUNDAMENTALS | |
---|---|
MarketCap: | 17.49 mill |
EPS: | 0.0400 |
P/E: | 4.88 |
Earnings Date: | Nov 13, 2023 |
SharesOutstanding: | 89.69 mill |
Avg Daily Volume: | 0.0149 mill |
RATING 2024-01-12 |
---|
A+ |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Strong Buy | |
P/E: | Strong Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | n/a | n/a | ||||
Ebit | n/a | |||||
Asset | n/a | |||||
Debt | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.17x |
Company: PE 4.88 | sector: PE 29.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.04x |
Company: PE 4.88 | industry: PE 136.10 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.341 - 0.419 ( +/- 10.26%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-21 | Feighan Edward F | Buy | 250 000 | Stock Option (Right to Buy) |
2023-12-21 | Cavanaugh Michael R. | Buy | 1 000 000 | Stock Option (Right to Buy) |
2023-12-21 | Celeste Richard F | Sell | 250 000 | Stock Option (Right to Buy) |
2023-12-21 | Cavanaugh Michael R. | Buy | 1 000 000 | Common Stock |
2023-12-21 | Feighan Edward F | Buy | 666 667 | Common Stock |
INSIDER POWER |
---|
-22.59 |
Last 100 transactions |
Buy: 50 695 925 | Sell: 38 639 634 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.195 (2.63% ) |
Volume | 0.0183 mill |
Avg. Vol. | 0.0149 mill |
% of Avg. Vol | 122.97 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Malachite Innovations, Inc., together with its subsidiaries, provides health and wellness products in the United States. It offers a portfolio of approximately 100 novel cannabosides, including glycosylated tetrahydrocannabinol, cannabidiol, cannabidivarin, and cannabinol. The company also develops THC-glycoside (VBX-100), an oral prodrug for the treatment of gastrointestinal diseases, including inflammatory bowel disease and irritable bowel syndrome. In addition, it engages in identifying, investing in, and repositioning environmental situations with a focus on technological innovations and eco-friendly solutions. The company was formerly known as Vitality Biopharma, Inc. and changed its name to Malachite Innovations, Inc. in October 2021. Malachite Innovations, Inc. was incorporated in 2007 and is headquartered in Cleveland, Ohio.